Oral drug treatment helps protect cancer patients from potentially deadly blood clots

May 11, 2018, University of Warwick

Research from the University of Warwick indicates that taking a tablet a day can help treat cancer patients of a potentially deadly condition.

People with have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) - either deep vein thrombosis (DVT) or pulmonary embolism (PE). Blood clots in the deep veins of the leg may travel to the lungs causing a pulmonary embolism. These two conditions are referred to as VTE—a dangerous and potentially deadly medical condition of which there are 10 million cases worldwide.

Current international guidelines recommend cancer patients are injected with an anticoagulant (a low molecular weight heparin) to treat and prevent recurrence of VTE. However, new results from a large pilot trial run at the University's Warwick Medical School called 'select-d' suggest that a daily tablet could be a beneficial alternative for treating VTE in selected patients.

Research led by Professor Annie Young of Warwick Medical School found that prescribing the oral drug (Xarelto) significantly reduced venous thromboembolism recurrence among patients with cancer and VTE. She said: "Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot."

Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility (if in bed poorly), pancreatic and gastric tumours, and chemotherapy. Because VTE can be life-threatening, blood thinners are used to shrink existing clots and prevent others from forming.

The 'select-d' trial enrolled 406 patients who had cancer and VTE; most (69 percent) were receiving cancer treatment (typically chemotherapy) at the time of their VTE. Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four percent among those taking the tablet and 11 percent in those receiving dalteparin.

The results for secondary outcomes were mixed. In receiving rivaroxaban, there were around the same percentage of major bleeding events (6 percent) as those receiving dalteparin (4 percent) but a marked and significant increase in clinically relevant non-major bleeds (13 percent) with rivaroxaban compared to those having low molecular weight heparin (4 percent). The reason for increased bleeding is not known, it may be because rivaroxaban is more 'potent'.

Professor Young added: "We now need to be sitting down with each one of our with VTE, discussing their preference alongside looking at all their clinical details including whether the cancer lesion is still there, what other medications are being taken and what other conditions the patient has so that we can choose the optimal VTE treatment for each patient."

Explore further: Rivaroxaban reduces VTE recurrence compared with aspirin

More information: Annie M. Young et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D), Journal of Clinical Oncology (2018). DOI: 10.1200/JCO.2018.78.8034

Related Stories

Rivaroxaban reduces VTE recurrence compared with aspirin

March 20, 2017
In patients at elevated risk for a recurrence of potentially life-threatening blood clots, a low dose of the oral blood-thinning medication rivaroxaban reduced recurrences more than three-fold compared with aspirin, with ...

New blood thinner better at preventing recurrent blood clots than aspirin

March 19, 2017
An international research team with prominent Canadian leadership has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs ...

Rivaroxaban OK for stroke prevention in cancer patients

July 13, 2017
(HealthDay)—The safety and efficacy of rivaroxaban treatment for nonvalvular atrial fibrillation (AF) in patients with active cancer is similar to the general population, according to a study published in the July 15 issue ...

Aspirin prevents venous thromboembolism following major orthopedic surgeries, study finds

March 13, 2018
A multicentre, double-blind, randomized, controlled clinical trial of patients who underwent total hip or knee replacement surgery showed that aspirin was as effective as rivaroxaban, the standard anti-coagulation medication, ...

Study compares heparin to warfarin for treatment of blood clots in patients with cancer

August 18, 2015
Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not ...

Blood thinner may protect cancer patients from potentially fatal clots

June 7, 2011
A new type of anti-clotting drug called semuloparin has been found to reduce the development of potentially fatal blood clots in the veins that often occur in cancer patients, doctors at Duke Cancer Institute and elsewhere ...

Recommended for you

As body mass index increases, blood pressure may as well

August 17, 2018
Body mass index is positively associated with blood pressure, according to the ongoing study of 1.7 million Chinese men and women being conducted by researchers at the Yale Center for Outcomes Research and Evaluation (CORE) ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Gout could increase heart disease risk

August 17, 2018
Having a type of inflammatory arthritis called gout may worsen heart-related outcomes for people being treated for coronary artery disease, according to new research.

Stroke patients treated at a teaching hospital are less likely to be readmitted

August 17, 2018
Stroke patients appear to receive better care at teaching hospitals with less of a chance of landing back in a hospital during the early stages of recovery, according to new research from The University of Texas Health Science ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.